326 related articles for article (PubMed ID: 17570558)
1. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
[TBL] [Abstract][Full Text] [Related]
2. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
Rahme E; Toubouti Y; Hunsche E
Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
[TBL] [Abstract][Full Text] [Related]
3. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum H; Bombardier C; Davis P; Russell AS;
J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
[TBL] [Abstract][Full Text] [Related]
4. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.
Shireman TI; Rigler SK
Am J Geriatr Pharmacother; 2006 Sep; 4(3):210-8. PubMed ID: 17062321
[TBL] [Abstract][Full Text] [Related]
5. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review.
Fischer MA; Cheng H; Schneeweiss S; Avorn J; Solomon DH
Med Care; 2006 Jul; 44(7):658-63. PubMed ID: 16799360
[TBL] [Abstract][Full Text] [Related]
6. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
7. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors.
Fischer MA; Schneeweiss S; Avorn J; Solomon DH
N Engl J Med; 2004 Nov; 351(21):2187-94. PubMed ID: 15548779
[TBL] [Abstract][Full Text] [Related]
8. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals.
Greenberg JD; Bingham CO; Abramson SB; Reed G; Kishimoto M; Hinkle K; Kremer J
Arthritis Rheum; 2006 Aug; 55(4):543-50. PubMed ID: 16874798
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Rahme E; Hunsche E; Toubouti Y; Chabot I
Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
[TBL] [Abstract][Full Text] [Related]
10. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study.
Sebaldt RJ; Petrie A; Goldsmith CH; Marentette MA
Am J Manag Care; 2004 Nov; 10(11 Pt 1):742-50. PubMed ID: 15623264
[TBL] [Abstract][Full Text] [Related]
11. Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.
Mosis G; Stijnen T; Castellsague J; Dieleman JP; van der Lei J; Stricker BH; Sturkenboom MC
Arthritis Rheum; 2006 Aug; 55(4):537-42. PubMed ID: 16874797
[TBL] [Abstract][Full Text] [Related]
12. Utilization and cost comparison of current and optimal prescribing of nonsteroidal antiinflammatory drugs in Quebec, Canada.
Rahme E; Toubouti Y; Lelorier J
J Rheumatol; 2006 Mar; 33(3):588-96. PubMed ID: 16463432
[TBL] [Abstract][Full Text] [Related]
13. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
14. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia.
Grootendorst P; Stewart D
Health Econ; 2006 Jul; 15(7):735-42. PubMed ID: 16498702
[TBL] [Abstract][Full Text] [Related]
15. Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario.
Mamdani M; Warren L; Kopp A; Paterson JM; Laupacis A; Bassett K; Anderson GM
CMAJ; 2006 Dec; 175(12):1535-8. PubMed ID: 17146090
[TBL] [Abstract][Full Text] [Related]
16. Using pharmacoepidemiology to inform drug coverage policy: initial lessons from a two-province collaborative.
Paterson JM; Laupacis A; Bassett K; Anderson GM;
Health Aff (Millwood); 2006; 25(5):1436-43. PubMed ID: 16966744
[TBL] [Abstract][Full Text] [Related]
17. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
Barozzi N; Tett SE
Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
[TBL] [Abstract][Full Text] [Related]
18. Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals.
Schüssel K; Schulz M
Pharmazie; 2006 Oct; 61(10):878-86. PubMed ID: 17069430
[TBL] [Abstract][Full Text] [Related]
19. Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis.
Marshall D; Gough J; Grootendorst P; Buitendyk M; Jaszewski B; Simonyi S; Jivraj F; Macleod S
J Health Serv Res Policy; 2006 Jan; 11(1):13-20. PubMed ID: 16378528
[TBL] [Abstract][Full Text] [Related]
20. Socioeconomic status, access to health care, and outcomes after acute myocardial infarction in Canada's universal health care system.
Pilote L; Tu JV; Humphries K; Behouli H; Belisle P; Austin PC; Joseph L
Med Care; 2007 Jul; 45(7):638-46. PubMed ID: 17571012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
